Ana Carolina Putini Vieira

Ana Carolina Putini Vieira

Auto-generated profile, based on publicly available information

Ana Carolina Putini Vieira

University of Santo Amaro, Department of Medicine, São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2025 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
ASArthur Carvalho Silva
Arthur Carvalho Silva
CFCamila Franco-Mesa
Camila Franco-Mesa
AVAna Carolina Putini Vieira
Ana Carolina Putini Vieira
ACAnelise Poluboiarinov Cappellaro
Anelise Poluboiarinov Cappellaro
EMEduardo Montag
Eduardo Montag
RGRolf Gemperli
Rolf Gemperli

18 October 2025 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
AVAna Carolina Putini Vieira
Ana Carolina Putini Vieira
MAMaria Antônia Costa Cruz Akabane
Maria Antônia Costa Cruz Akabane
GCGianna Carolinne Graff Caletti
Gianna Carolinne Graff Caletti
KHKélen Klein Heffel
Kélen Klein Heffel
ASAmanda Tauana Oliveira e Silva
Amanda Tauana Oliveira e Silva
Prurigo nodularis (PN) is a chronic, debilitating inflammatory skin disorder characterized by persistent itching, firm pruritic nodular lesions, and evidence of frequent scratching, like excoriation, and lichenification. Nemolizumab, a monoclonal antibody targeting IL-31, has shown significant improvements in skin lesions, itching, and sleep disturbances by reducing type 2 immune responses in PN. Evaluate the efficacy and safety of nemolizumab in treating PN by systematically analyzing randomized controlled trials (RCTs). The authors conducted a systematic review and meta-analysis by searching Pubmed, Embase, Cochrane Central and Scopus for RCTs comparing nemolizumab to placebo for PN. Statistical analysis usedR Studio 4.3.2. Three trials, involving 630 patients, were included. Nemolizumab significantly reduced pruritus at week-4 (MD = -32.04; 95% CI: -38.47, -25.62) and at week-16 (MD = -347.34; 95% CI: -1039.71, 345.04). Investigator's Global Assessment (IGA) success favored Nemolizumab at week-16 (RR = 3.50; 95% CI: 2.18, 5.63). No significant differences were observed in adverse events (RR = 1.10; 95% CI: 0.97, 1.25) or serious adverse events (RR = 0.77; 95% CI: 0.43, 1.39). Nemolizumab also significantly reduced neurodermatitis. Limitations include variability in treatment duration, small sample sizes, and the lack of direct comparisons with other biologics. Our meta-analysis shows that Nemolizumab significantly improves pruritus, IGA success rates, and PAS > 75% in treating patients with moderate to severe PN. Its safety profile is favorable, with no significant differences in adverse events compared to placebo. These findings support Nemolizumab as a viable treatment for moderate to severe PN.

15 February 2025 in Inflammopharmacology
Verified
Journal Article
Closed access
MPMable Pereira
Mable Pereira
AFAncy Jenil Franco
Ancy Jenil Franco
KCKarthik Chintharala
Karthik Chintharala
AVAna Carolina Putini Vieira
Ana Carolina Putini Vieira
AJAna Carolina Ventura de Santana de Jesus
Ana Carolina Ventura de Santana de Jesus
KRKristian Reich
Kristian Reich

8 January 2026 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
AVAna Carolina Putini Vieira
Ana Carolina Putini Vieira
FLFernanda Cronemberger Lins
Fernanda Cronemberger Lins
ABArianne Costa Baquião
Arianne Costa Baquião
Cutaneous Leishmaniasis (CL) affects up to 1.2 million people annually, mainly in resource-limited regions. Meglumine antimoniate, the standard treatment, is limited by systemic toxicity, injectable administration, and increasing resistance. Miltefosine, an oral alternative, offers practical advantages, although comparative efficacy and safety data remain inconsistent. To compare the efficacy and safety of miltefosine versus meglumine antimoniate for New World CL. The authors systematically searched PubMed, Embase, Scopus, and the Cochrane Library for randomized controlled trials directly comparing miltefosine and meglumine antimoniate. Risk Ratios (RRs) with 95% Confidence Intervals (95% CIs) were calculated using random-effects models. Heterogeneity was assessed with the I² statistic. Risk of bias was evaluated using the Cochrane RoB-2 tool. Certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach. Eight trials involving 898 patients (502 treated with miltefosine, 396 with meglumine antimoniate) were included. Miltefosine showed significantly higher cure rates at two months (RR = 0.83; 95% CI: 0.71-0.98; I2 = 0%). Differences at six months were not statistically significant. Gastrointestinal side effects were more frequent with miltefosine, whereas hepatic enzyme elevations, arthralgia (RR = 10.08; 95% CI: 2.36-43.12), and fever (RR = 2.98; 95% CI: 1.53-5.80) were more common with meglumine antimoniate. High heterogeneity, short follow-up, small sample sizes, and interstudy variability may limit precision. Miltefosine shows superior early response and a safer systemic profile. However, the certainty of evidence, as assessed by GRADE, ranged from very low to high across outcomes, and long-term data remain limited, highlighting the need for further high-quality studies with extended follow-up.

9 July 2026 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
MKMichele Kreuz
Michele Kreuz
AVAna Carolina Putini Vieira
Ana Carolina Putini Vieira
AJAna Carolina Ventura de Santana de Jesus
Ana Carolina Ventura de Santana de Jesus
LVLuisa Medeiros Visentini
Luisa Medeiros Visentini
LOLilia Maria Lima de Oliveira
Lilia Maria Lima de Oliveira
AQAbrar A Qureshi
Abrar A Qureshi

13 June 2026 in Clinical and Translational Oncology
Verified
Journal Article
Open access
ABAnne Gabriela Silva Batista
Anne Gabriela Silva Batista
CPCarolinny Silva Ribeiro Pereira
Carolinny Silva Ribeiro Pereira
EDEduardo Henrique Isgarbose Durello
Eduardo Henrique Isgarbose Durello
AVAna Carolina Putini Vieira
Ana Carolina Putini Vieira
HJHézio Jadir Fernandes Junior
Hézio Jadir Fernandes Junior
Introduction: Glioblastoma (GBM) remains the most aggressive primary brain tumor, with poor prognosis and limited therapeutic options. Immune checkpoint inhibitors have shown promising results in solid tumors, but their role in GBM remains uncertain. Methods: A PRISMA-based systematic review and meta-analysis including studies evaluating checkpoint inhibitors in newly diagnosed and recurrent GBM. Random-effects models calculated pooled hazard ratios for OS and PFS. Results: Eleven studies were included, six ( n = 2,019) incorporated into pooled survival analyses. No significant OS benefit was observed (HR = 1.12; 95% CI: 0.97–1.29; I 2 = 0%; p = 0.138). PFS showed significant differences (HR = 1.34; 95% CI: 1.06–1.68; I 2 = 74.3%; p = 0.013). Grade ≥ 3 toxicity occurred in 32.1% of patients. Conclusion: Checkpoint inhibitors did not significantly improve OS or PFS in GBM patients and were associated with substantial toxicity and inter-study heterogeneity.